Results for binjurebarksuppression translation from Swedish to English

fall av cushing´s syndrom och binjurebarksuppression har rapporterats.
cases of cushing’s syndrome and adrenal suppression have been reported.

långtidsbehandling med inhalationssteroider i höga doser kan leda till binjurebarksuppression och akut binjurebarkkris.
as with other inhalation therapy paradoxical bronchospasm may occur with an immediate increase in wheezing after dosing.

kronisk överdosering med flutikasonpropionat i inhalation: se under 4. 4 risk för binjurebarksuppression.
there have been very rare reports of hyperglycaemia (see 4.4 special warnings and precautions for use).

behandling med nasala kortikosteroider i högre doser än rekommenderade doser kan orsaka kliniskt betydelsefull binjurebarksuppression.
treatment with higher than recommended doses of nasal corticosteroids may result in clinically significant adrenal suppression.

patienter med infantilt hemangiom kan löpa ökad risk om de har fått eller får samtidig behandling med kortikosteroider eftersom binjurebarksuppression kan resultera i bortfall av den motverkande kortisolresponsen och ökar risken för hypoglykemi.
patients with infantile haemangioma may be at increased risk if they have received or are concomitantly receiving treatment with corticosteroids because adrenal suppression may result in loss of the counterregulatory cortisol response and increase the risk of hypoglycaemia.

cushing´s syndrom, cushingliknande symtombild, mycket binjurebarksuppression, hämmad längdtillväxt hos barn och ungdomar, minskad bentäthet, katarakt och glaukom
cushing’ s syndrome, cushingoid features, adrenal suppression, growth retardation in children and adolescents, decreased bone mineral density, cataract, glaucoma

cushing’ s syndrom, cushingliknande symtombild, mycket sällsynta binjurebarksuppression, hämmad längdtillväxt hos barn och ungdomar, minskad bentäthet, katarakt och glaukom
very rare events were derived from post- marketing spontaneous data.

eventuella systembiverkningar inkluderar cushing’ s syndrom, cushingliknande symtombild, binjurebarksuppression, hämmad längdtillväxt hos barn och ungdomar, minskad bentäthet, katarakt och glaukom.
there have been very rare reports of increases in blood glucose levels (see 4.8 undesirable effects) and this should be considered when prescribing to patients with a history of diabetes mellitus.

systemeffekter av kortikosteroider, inklusive cushings syndrom och binjurebarksuppression har rapporterats hos patienter som fått ritonavir samtidigt med inhalerat eller intranasalt administrerat flutikasonpropionat; detta kan också inträffa med andra kortikosteroider som metaboliseras via cytokrom p450 3a, t ex budesonid.
systemic corticosteroid effects including cushing’s syndrome and adrenal suppression have been reported in patients receiving ritonavir and inhaled or intranasally administered fluticasone propionate; this could also occur with other corticosteroids metabolised via the p450 3a pathway e.g. budesonide.

eventuella systembiverkningar inkluderar cushing´s syndrom, cushingliknande symtombild, binjurebarksuppression, hämmad längdtillväxt hos barn och ungdomar, minskad bentäthet, katarakt och glaukom (se 4. 4 varningar och försiktighetsmått).
possible systemic effects include cushing’ s syndrome, cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma (see 4.4 special warnings and precautions for use).